Trial Search Results

Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome

The purpose of this study is to determine whether the medication oxytocin is an effective and tolerable treatment in adolescent males with fragile X syndrome (FraX) for improving socially appropriate behaviors and reducing social anxiety.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Drug: placebo
  • Drug: oxytocin 24IU
  • Drug: oxytocin 48IU

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   1. Confirmed genetic diagnosis of Fragile X (FraX) (full mutation).

   2. Male (who have more serious effects due to the X chromosome nature of the disorder)

   3. Age 13-29 years.

   4. Parent of adolescent must be willing to sign informed consent.

   5. Intelligence Quotient (IQ) > 42.

Exclusion Criteria:

   1. Cardiac risk factors.

   2. Medication exclusions: opiates or opiate antagonists, corticosteroids, typical or
   atypical antipsychotics.

Ages Eligible for Study

13 Years - 29 Years

Genders Eligible for Study

Male

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Scott Hall
6504984799
Not Recruiting